Polyglutamate camptothecin clinical trials
Also written CT-2106.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2003
How each study uses polyglutamate camptothecin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2004 (2)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
CTI BioPharma (2) · Memorial Sloan Kettering Cancer Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses polyglutamate camptothecin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Polyglutamate Camptothecin in Treating Patients With Advanced CancerCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT00059917Written as polyglutamate camptothecin
- Phase I/II CT 2106 and 5-FU/FA in Colorectal CancerCompletedPhase 1/2CTI BioPharmaNCT00291785Written as CT-2106
- CT-2106 for the Second Line Treatment of Ovarian CancerCompletedPhase 2CTI BioPharmaNCT00291837Written as CT-2106